Shanmugam Rengasamy P, Balakrishnan Selvakumar, Varadhan Hemalatha, Shanmugam Vivekanandan
Founding Trustee - Chennai Liver Foundation, Chennai.
Liver Unit, Kovai Medical Center and Hospital.
Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1344-1351. doi: 10.1097/MEG.0000000000001180.
This study aims to estimate the prevalence of hepatitis B (HBV) and C (HCV) in the population through field-screening camps conducted by Chennai Liver Foundation, in the southern state of Tamil Nadu, India. This is the largest population-based study from Tamil Nadu.
A total of 75 camps were conducted across 14 districts of Tamil Nadu (2014-2017). Screening was done by rapid point-of-care assays (SD-bioline tests) and confirmed by enzyme-linked immunosorbent assay (Monolisa tests). Those tested negative were offered first dose of HBV vaccine. Positive patients with HBV count of more than 2000 IU/ml or HCV-RNA positive on quantitative analysis were treated.
A total of 18 589 people were screened, with HBV infection detected in 303 (prevalence 1.63%) and HCV infection in 56 (prevalence 0.3%), with significant variation among districts. Males contributed to about three-fourths of detected HBV [233/303 (77%)] or HCV [41/56 (73%)] infection. Screening detected a higher overall HBV/HCV infection rate in rural [203 (2.52%) infections in 8047 people] than in urban [156 (1.47%) infections in 10 542 people] areas (P<0.0001). Slum areas had a HBV prevalence of 5%. In a dialysis unit, all patients were found to have either HBV/HCV infection. A total of 162/303 (54%) people with HBV and 27/56 (48%) with HCV infection were treated, and 7704 people received the first dose of HBV vaccine.
The prevalence of HBV was 1.63% and HCV was 0.30% in Tamil Nadu. Three-fourths of HBV/HCV infected people were males. Prevalence of HBV/HCV was higher in rural areas. Slum area and dialysis unit had high HBV and HCV prevalence.
本研究旨在通过印度南部泰米尔纳德邦金奈肝脏基金会开展的现场筛查营地，估算该人群中乙型肝炎（HBV）和丙型肝炎（HCV）的患病率。这是来自泰米尔纳德邦规模最大的基于人群的研究。
在泰米尔纳德邦的14个区共开展了75个营地筛查（2014 - 2017年）。筛查采用即时快速检测法（SD生物线检测），并通过酶联免疫吸附测定法（伯乐酶免检测）进行确认。检测结果为阴性的人员接种第一剂乙肝疫苗。对乙肝病毒载量超过2000 IU/ml或定量分析丙肝病毒核糖核酸呈阳性的阳性患者进行治疗。
共筛查了18589人，检测出303人感染乙肝病毒（患病率1.63%），56人感染丙肝病毒（患病率0.3%），各地区之间存在显著差异。感染乙肝病毒[233/303（77%）]或丙肝病毒[41/56（73%）]的人群中约四分之三为男性。筛查发现农村地区乙肝病毒/丙肝病毒总体感染率[8047人中203人（2.52%）感染]高于城市地区[10542人中156人（1.47%）感染]（P<0.0001）。贫民窟地区乙肝病毒患病率为5%。在一个透析单元中，所有患者均被发现感染了乙肝病毒/丙肝病毒。共有162/303（54%）的乙肝病毒感染者和27/56（48%）的丙肝病毒感染者接受了治疗，7704人接种了第一剂乙肝疫苗。
泰米尔纳德邦乙肝病毒患病率为1.63%，丙肝病毒患病率为0.30%。乙肝病毒/丙肝病毒感染者中约四分之三为男性。农村地区乙肝病毒/丙肝病毒患病率较高。贫民窟地区和透析单元乙肝病毒和丙肝病毒患病率较高。
